Hypha’s Q1 2017 newsletter – Accessing structurally-unknown metabolites for MIST compliance – a case study

This quarter we illustrate a case study describing the successful provision of hundreds of milligrams of a major hydroxylated metabolite to a client for unambiguous structure determination and, critically, for biological tests requested by the FDA. The topical dermal drug is currently in Phase 3 clinical trials and access to scalable amounts of the metabolite was important in satisfying aspects of safety testing for MIST compliance.

Click on the link below for more information on this project.

Hypha newsletter Q1 2017